In vitro uptake and release of natamycin from conventional and silicone hydrogel contact lens materials

Eye and Contact Lens

Volumn 39, Issue 2, 2013, Pages 162-168

  Phan, Chau Minh ^a   Subbaraman, Lakshman N ^a   Jones, Lyndon ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; NATAMYCIN; SILICONE; SILICONE HYDROGEL; UNCLASSIFIED DRUG;

ARTICLE; CONTACT LENS; DRUG RELEASE; DRUG UPTAKE; IN VITRO STUDY; PRIORITY JOURNAL; ULTRAVIOLET SPECTROPHOTOMETRY;

ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; CONTACT LENSES, HYDROPHILIC; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EYE INFECTIONS, FUNGAL; HUMANS; HYDROGELS; NATAMYCIN; SILICONES; SPECTROPHOTOMETRY; TIME FACTORS;

EID: 84874947091     PISSN: 15422321     EISSN: 1542233X     Source Type: Journal    
DOI: 10.1097/ICL.0b013e31827a7a07     Document Type: Article

References (62)

1. Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. Bull World Health Organ 2001;79:214-221.
2. Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev 2003;16:730-797.
3. Bharathi MJ, Ramakrishnan R, Vasu S, et al. Epidemiological characteristics and laboratory diagnosis of fungal keratitis. A three-year study. Indian J Ophthalmol 2003;51:315.
4. Leck A, Thomas P, Hagan M, et al. Aetiology of suppurative corneal ulcers in Ghana and south India, and epidemiology of fungal keratitis. Br J Ophthalmol 2002;86:1211.
5. Bharathi MJ, Ramakrishnan R, Shivakumar C, et al. Etiology and antibacterial susceptibility pattern of community-acquired bacterial ocular infections in a tertiary eye care hospital in south India. Indian J Ophthalmol 2010;58:497-507.
6. Bandyopadhyay S, Das D, Mondal KK, et al. Epidemiology and laboratory diagnosis of fungal corneal ulcer in the Sundarban Region of West Bengal, eastern India. Nepal J Ophthalmol 2012;4:29-36.
7. Katiyar R, Deorukhkar S, Saini S. Epidemiological features and laboratory results of bacterial and fungal keratitis: a five-year study at a rural tertiarycare hospital in western Maharashtra, India. Singapore Med J 2012;53: 264-267.
8. Xuguang S, Zhixin W, Zhiqun W, et al. Ocular fungal isolates and antifungal susceptibility in northern China. Am J Ophthalmol 2007;143:131-133.
9. Sun XG, Zhang Y, Li R, et al. Etiological analysis on ocular fungal infection in the period of 1989-2000. Chin Med J (Engl) 2004;117:598-600.
10. Asbell P, Stenson S. Ulcerative keratitis: survey of 30 years' laboratory experience. Arch Ophthalmol 1982;100:77.
11. FlorCruz NV, Peczon IV, Evans Jr. Medical interventions for fungal keratitis. Cochrane Database Syst Rev 2012;2:CD004241.
12. Luisa HL. Therapeutic contact lens-related bilateral fungal keratitis. Eye Contact Lens 2002;28:149.
13. Choi DM, Goldstein MH, Salierno A, et al. Fungal keratitis in a daily disposable soft contact lens wearer. Eye Contact Lens 2001;27:111-112.
14. Le Liboux M, Ibara S, Quinio D, et al. Fungal keratitis in a daily disposable soft contact lens wearer. J Fr Ophtalmol 2004;27:401.
15. Elder BL, Bullock JD, Warwar RE, et al. Pan-antimicrobial failure of alexidine as a contact lens disinfectant when heated in Bausch & Lomb plastic containers: implications for the worldwide Fusarium keratitis epidemic of 2004 to 2006. Eye Contact Lens 2012;38:222-226.
16. Yildiz EH, Abdalla YF, Elsahn AF, et al. Update on fungal keratitis from 1999 to 2008. Cornea 2010;29:1406-1411.
17. Bullock JD, Elder BL, Khamis HJ, et al. Effects of time, temperature, and storage container on the growth of Fusarium species: implications for the worldwide Fusarium keratitis epidemic of 2004-2006. Arch Ophthalmol 2011;129:133-136.
18. Agarwal PK, Roy P, Das A, et al. Efficacy of topical and systemic itraconazole as a broad-spectrum antifungal agent in mycotic corneal ulcer. A preliminary study. Indian J Ophthalmol 2001;49:173.
19. Kaur IP, Rana C, Singh H. Development of effective ocular preparations of antifungal agents. J Ocul Pharmacol Ther 2008;24:481-494.
20. Le Bourlais C, Acar L, Zia H, et al. Ophthalmic drug delivery systems- recent advances. Prog Retin Eye Res 1998;17:33-58.
21. Wichterle O, Lim D. Hydrophilic gels for biological use. Nature 1960;185: 117-118.
22. Sedlacek J. Possibilities of application of eye drugs with the aid of gelcontact lenses. Cesk Oftalmol 1965;21:509-512.
23. Fonn D, Bruce AS. A review of the Holden-Mertz criteria for critical oxygen transmission. Eye Contact Lens 2005;31:247.
24. Holden BA, Sankaridurg PR, Sweeney DF, et al. Microbial keratitis in prospective studies of extended wear with disposable hydrogel contact lenses. Cornea 2005;24:156.
25. Stapleton F, Stretton S, Papas E, et al. Silicone hydrogel contact lenses and the ocular surface. Ocul Surf 2006;4:24-43.
26. Brennan NA, Coles M, Comstock TL, et al. A 1-year prospective clinical trial of balafilcon A (PureVision) silicone-hydrogel contact lenses used on a 30-day continuous wear schedule. Ophthalmology 2002;109:1172-1177.
27. Lim L, Tan D, Chan WK. Therapeutic use of Bausch & Lomb PureVision contact lenses. CLAO J 2001;27:179.
28. Bendoriene J, Vogt U. Therapeutic use of silicone hydrogel contact lenses in children. Eye Contact Lens 2006;32:104.
29. Ciolino JB, Dohlman CH, Kohane DS. Contact lenses for drug delivery. Semin Ophthalmol 2009;24:156-160.
30. Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 2004;45:2342-2347.
31. Peng CC, Chauhan A. Extended cyclosporine delivery by silicone-hydrogel contact lenses. J Control Release 2011;154:267-274.
32. Peng CC, Kim J, Chauhan A. Extended delivery of hydrophilic drugs from silicone-hydrogel contact lenses containing vitamin E diffusion barriers. Biomaterials 2010;31:4032-4047.
33. Kim J, Conway A, Chauhan A. Extended delivery of ophthalmic drugs by silicone hydrogel contact lenses. Biomaterials 2008;29:2259-2269.
34. O'Day DM. Selection of appropriate antifungal therapy. Cornea 1987; 6:238.
35. Loh AR, Hong K, Lee S, et al. Practice patterns in the management of fungal corneal ulcers. Cornea 2009;28:856.
36. O'Brien TP. Therapy of ocular fungal infections. Ophthalmol Clin North Am 1999;12:33-50.
37. te Welscher YM, Hendrik H, Balagué MM, et al. Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem 2008;283:6393-6401.
38. Kaur IP, Kakkar S. Topical delivery of antifungal agents. Expert Opin Drug Deliv 2010;7:1303-1327.
39. Hui A, Boone A, Jones L. Uptake and release of ciprofloxacin-HCl from conventional and silicone hydrogel contact lens materials. Eye Contact Lens 2008;34:266.
40. Karlgard C, Jones L, Moresoli C. Ciprofloxacin interaction with siliconbased and conventional hydrogel contact lenses. Eye Contact Lens 2003; 29:83.
41. Karlgard C, Wong N, Jones L, et al. In vitro uptake and release studies of ocular pharmaceutical agents by silicon-containing and p-HEMA hydrogel contact lens materials. Int J Pharm 2003;257:141-151.
42. Boone A, Hui A, Jones L. Uptake and release of dexamethasone phosphate from silicone hydrogel and group I, II, and IV hydrogel contact lenses. Eye Contact Lens 2009;35:260-267.
43. Jones L, Subbaraman L, Rogers R, et al. Surface treatment, wetting and modulus of silicone hydrogels. Optician 2006;232:28-34.
44. Subbaraman LN, Jones L. Kinetics of lysozyme activity recovered from conventional and silicone hydrogel contact lens materials. J Biomater Sci Polym Ed 2010;21:343-358.
45. Schaffner CP, Mechlinski W. Polyene macrolide derivatives. II. Physicalchemical properties of polyene macrolide esters and their water soluble salts. J Antibiot (Tokyo) 1972;25:259.
46. Lalitha P, Vijaykumar R, Prajna N, et al. In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder. J Clin Microbiol 2008;46:3477.
47. Capitan-Vallvey LF, Checa-Moreno R, Navas N. Rapid ultraviolet spectrophotometric and liquid chromatographic methods for the determination of natamycin in lactoserum matrix. J AOAC Int 2000;83:802-808.
48. Efron N, Young G, Brennan NA. Ocular surface temperature. Curr Eye Res 1989;8:901-906.
49. Thomas A. Analysis and assay of polyene antifungal antibiotics. A review. Analyst 1976;101:321-340.
50. Wood DC, Wood J. Pharmacologic and biochemical considerations of dimethyl sulfoxide. Ann N Y Acad Sci 1975;243:7-19.
51. Silverman CA, Yoshizumi MO. Ocular toxicity of experimental intravitreal DMSO. Cutan Ocul Toxicol 1983;2:193-200.
52. Yoshizumi MO, Banihashemi A. Experimental intravitreal ketoconazole in DMSO. Retina 1988;8:210.
53. Schulman J, Peyman G, Dietlein J, et al. Ocular toxicity of experimental intravitreal itraconazole. Int Ophthalmol 1991;15:21-24.
54. Marc OY, Vinci V, Karyn DF. Toxicity of intravitreal miconazole in DMSO. Cutan Ocul Toxicol 1987;6:19-27.
55. Creech J, Chauhan A, Radke C. Dispersive mixing in the posterior tear film under a soft contact lens. Ind Eng Chem Res 2001;40:3015-3026.
56. McNamara NA, Polse KA, Brand RJ, et al. Tear mixing under a soft contact lens: Effects of lens diameter. Am J Ophthalmol 1999;127:659-665.
57. Arora R, Jain S, Monga S, et al. Efficacy of continuous wear PureVision contact lenses for therapeutic use. Cont Lens Anterior Eye 2004;27:39-43.
58. Foulks G, Harvey T, Raj C. Therapeutic contact lenses: The role of high-Dk lenses. Ophthalmol Clin North Am 2003;16:455.
59. López-Alemany A, Compañ V, Refojo MF. Porous structure of Purevision ™ versus Focus- Night&Day™ and conventional hydrogel contact lenses. J Biomed Mater Res 2002;63:319-325.
60. Haller I, Plempel M. Experimental in vitro and in vivo comparison of modern antimycotics. Curr Med Res Opin 1977;5:315-327.
61. Xu Y, Pang G, Gao C, et al. In vitro comparison of the efficacies of natamycin and silver nitrate against ocular fungi. Antimicrob Agents Chemother 2009;53:1636-1638.
62. Yolton DP. Antiinfective drugs. In: Bartlett JD, Jaanus SD, eds. Clinical Ocular Pharmacology, 4th ed. Woburn, MA: Butterworth-Heineman, 2001, pp 219-264.